Among research news last week, Gilead Sciences released positive new Phase III data on progression fee survival for its Trodelvy plus Keytruda in breast cancer. Roivant company Immunovant last week announced significant executive changes and development activities, notably on batoclimab and IMVT-1402. France’s Innate Pharma announced revisions to its collaboration with Sanofi on their ANKET program. Merck & Co was among a number pharma major reporting first-quarter 2025 financial results that beat expectations. 27 April 2025
Zurich-based biotech MetrioPharm has appointed Stephan Rietiker as chair of its board of directors, following a unanimous vote by the newly formed board. 24 April 2025
Denmark’s Zealand Pharma, a company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Utpal Singh as chief scientific officer. 24 April 2025
Autoimmune diseases specialist Immunovant has announced changes to its leadership team and the expanded development of its drug IMVT-1402 into two new indications, Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE). 23 April 2025
US clinical-stage biotech Halda Therapeutics today announced that Dr Eyal Attar has joined the company as chief medical officer (CMO). Dr Attar brings to Halda over 25 years of biotechnology R&D and clinical trial experience in the advancement of novel therapeutics. 22 April 2025
Galapagos has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a major step in the company’s planned division into two focused businesses. 22 April 2025
Zymeworks, a clinical-stage biotech developing antibody-based therapies for cancer and immune diseases, has appointed Sabeen Mekan as senior vice president of clinical development. 22 April 2025
Australian clinical-stage biotech Neurizon Therapeutics, which is advancing innovative treatments for neurodegenerative diseases, has significantly strengthened its executive management team with three key appointments. 18 April 2025
Galapagos said on Tuesday that its chief financial officer and chief operating officer Thad Huston will leave the company on August 1, 2025, to return to the USA for personal and professional reasons. 15 April 2025
Dutch rare diseases biotech firm ProQR Therapeutics today announced the appointment of Dr Cristina Lopez Lopez as chief medical officer (CMO). 14 April 2025
US clinical-stage biotech Imbria Pharmaceuticals, which is focused on cardiometabolic diseases with high unmet need, says it has closed a $57.5 million Seres B financing. 10 April 2025
Privately-held Finland-based Valo Therapeutics (ValoTx), an immunotherapy company developing novel, adaptable treatments for cancer, today announced the appointment of Marcella Origgi as its chief executive (CEO) of its Helsinki headquarters and Naples, Italy, subsidiary. 9 April 2025
Myricx Bio, a UK biotech focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is expanding its team. 8 April 2025
China-based biotech DualityBio has named Hua Mu as its global chief medical officer, as the company prepares to ramp up its international clinical development efforts and advance toward key capital market milestones. 7 April 2025
Italy-based Angelini Ventures, the corporate venture arm of Angelini Industries, has named Regina Hodits as managing director as it looks to scale its biotech investment activities across Europe and North America. 7 April 2025
Swedish biotech OncoZenge has expanded its regulatory team as it prepares for a Phase III trial of BupiZenge (bupivacaine), a non-opioid treatment for oral pain caused by cancer therapies. 4 April 2025
US neuroscience-focused biopharma Neurocrine Biosciences today announced the appointment of Sanjay Keswani to the company's executive management team as chief medical officer (CMO) effective June 2, 2025. 4 April 2025
Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses as chairman. 4 April 2025
Israel-based Medison, a creator of a first-of-its-kind unified global commercialization platform that accelerates the launch of breakthrough therapies, has announced two key additions to its global leadership team: Shay Tamari as chief business officer (CBO) and Tali Mirsky as chief legal and compliance officer (CLCO). 19 June 2025
Australian biotech PolyActiva has brought in seasoned pharma executive Jerry St Peter as chief executive, in a leadership shake-up timed with a fresh $25 million financing round and a push to commercialize its lead eye implant therapy in the USA. 19 June 2025
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Symbiosis Pharmaceutical Services (Symbiosis), a global contract manufacturing organization (CMO) specializing in sterile manufacture of injectable drug products, has appointed Angelika Rublack as senior business development manager to support its expanding global client base and drive growth across several territories. 13 June 2025
US clinical-stage biotech Oncolytics Biotech today announced the appointment of Jared Kelly as chief executive (CEO) and a member of its board of directors. 11 June 2025
US ophthalmic gene therapy company Beacon Therapeutics, which is focused on restoring the vision of patients with blinding retinal diseases, has appointed Daniel Chung as chief medical officer (CMO). 9 June 2025
France-based SparingVision, a genomic medicine company focused on the treatment of retinal disease, has announced the appointment of Kalliopi ‘Kali’ Stasi, as chief medical officer, effective immediately. 9 June 2025
US cardiorenal-focussed drugmaker Ardelyx announced that Mike Kelliher, formerly executive vice president, corporate development and strategy, has been promoted to chief business officer, and James Brady has joined the company as chief human resources officer. 6 June 2025
Danish dermatology specialist LEO Pharma has appointed Helle Hedegaard Juhl as executive vice president for global people and corporate affairs (GPCA). 4 June 2025
Netherlands-based biotech VectorY Therapeutics, which is developing treatments for neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). 2 June 2025
Swiss biotech iOnctura has appointed Steven Sciuto as chief financial officer and Michelle Tsai as chief operating officer, marking a leadership shift as the company moves deeper into Phase II trials for its lead cancer candidate, roginolisib (IOA-244). 2 June 2025
US biotech Hillstar Bio has appointed Maude Tessier as chief operating officer and Shiva Krupa as vice president of program management, reinforcing its leadership bench ahead of a planned clinical entry for its lead autoimmune program in 2026. 29 May 2025
Swedish biotech Hansa Biopharma is preparing to reduce its headcount by around one-fifth as part of a restructuring plan aimed at sharpening operational focus and reducing costs. 27 May 2025
UK biotech Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer, a move that strengthens its leadership as it advances its pipeline of antibody therapies for inflammatory diseases. 27 May 2025
USA-based nonprofit CureDuchenne has announced the appointment of Brenda Wong as its new chief medical advisor (CMA), effective January 5, 2026. 22 May 2025